trial

Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

NCTId NCT00645944
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 39 (actual)
Sponsored by Yale University
Primary completion 2011-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-04
Primary completion
2011-04
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
eszopiclone

Sponsors

Yale UniversityLead Sponsor
Sumitomo Pharmaceuticals AmericaCollaborator

Investigators

1
Cenk Tek, M.D.Principal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
39
Phase
NA
Primary Completion Date
2011-04
Status
COMPLETED
relationships
The graph out of here
drug
eszopiclone
drug
lead_sponsor
Yale University
company
collaborator
Sumitomo Pharmaceuticals America
company
indication
Sleep Initiation and Maintenance Disorders
indication
Sleep Wake Disorders
indication
Schizoaffective Disorder
indication
investigator
Cenk Tek, M.D.
person